Blueprint Medicines Corporation (NASDAQ:BPMC) has submitted a supplemental New Drug Application to the US FDA for AYVAKIT™ (avapritinib) in treating advanced systemic mastocytosis (SM) patients. AYVAKIt is the company’s potent, selective D816B mutant KIT...
